Genetics and Biology: Understanding the Root Cause
At a Glance
Proximal tubulopathy-diabetes syndrome is linked to problems in the cell's energy-making system. Genetic changes can affect kidney tubules, insulin-producing pancreatic cells, and the brain, while different mixtures of healthy and altered mitochondria help explain varying symptoms and test results.
To understand mitochondrial disease, it helps to think of your cells as miniature cities. Every city needs a power plant to function. In your cells, those power plants are the mitochondria. They take the food you eat and the oxygen you breathe and turn them into ATP (adenosine triphosphate), the primary energy currency that powers almost every biological process in your body [1].
When you have a mitochondrial disease, these power plants are damaged or inefficient. This doesn’t affect every organ equally; instead, it hits the “high-energy” neighborhoods the hardest. Your brain, kidneys, and pancreas are like the heavy industrial zones of the cellular city—they require a massive, constant supply of ATP to work [2][3][4]. When the energy supply fails, these specific organs are often the first to show symptoms, creating a “triad” of health challenges.
The Genetic Blueprint: mtDNA vs. Nuclear DNA
Most of your DNA is kept in the cell’s nucleus (the “city hall”). However, mitochondria are unique because they have their own separate set of DNA, called mtDNA. You can think of the nucleus as the master blueprint for the whole city, while mtDNA is the specific instruction manual for the power plant itself.
Mitochondrial diseases can be caused by mistakes (mutations) in either manual:
- mtDNA Mutations: These are often passed down from the mother, though de novo (new) variants can occur, and an absence of family history does not rule the condition out. Common examples include the m.3243A>G mutation, which affects how the mitochondria build their internal machinery [1].
- Large-Scale Deletions: Sometimes, large chunks of the mtDNA manual are missing entirely, as seen in disorders like Kearns-Sayre syndrome. This partial defect in oxidative phosphorylation means the cell struggles for energy and may increase its reliance on a less efficient backup system called glycolysis [5][6]. Kearns-Sayre is a distinct deletion disorder, but deletions can cause overlapping symptoms.
- Nuclear Gene Mutations: Genes in your main DNA (like POLG or TWNK) are responsible for maintaining and copying the mtDNA. If these genes are broken, the power plant manual becomes corrupted over time [7].
Genetic Counseling: Genetic counseling is incredibly important for addressing family testing, reproductive decisions, and explaining how your specific nuclear or mtDNA finding affects you.
Understanding Heteroplasmy: The “Mixed Population”
One of the most confusing parts of mitochondrial disease is why two people with the same mutation can feel so different. This is due to heteroplasmy.
Unlike your nuclear DNA, where every cell generally has the same code, a single cell can contain hundreds of mitochondria. Heteroplasmy is the coexistence of healthy mitochondria and mutated mitochondria within the same cell [8].
- The Threshold Effect: Most people don’t show symptoms until the “load” of mutated mitochondria crosses a certain percentage—often called a threshold. As a simplified illustration, if 20% of your mitochondria are mutated, you might feel fine; if 80% are mutated, the organ may begin to fail. However, there is no universal threshold; levels vary substantially by variant, tissue, cell type, and age [8][9].
- Symptom Variability: Because mitochondria divide and distribute randomly as cells grow, one organ (like your kidneys) might end up with a high load of mutations, while another organ (like your skin) has very few. This explains why some patients have severe brain symptoms but healthy kidneys, while others have the opposite [10][11].
- Changes Over Time: In some cases, the percentage of mutated mitochondria in your blood can actually decrease as you age, while the load in your muscles or brain stays high. A blood result does not reliably predict brain, kidney, or muscle involvement [12].
Why Certain Organs Fail
The “phenotypic triad” of the brain, kidneys, and pancreas occurs because these organs are “energy hungry.”
- The Pancreas: To release insulin correctly, beta cells in the pancreas must detect sugar and produce a burst of ATP. If the mitochondria are failing, the ATP “signal” never happens, and the body can’t manage blood sugar, leading to mitochondrial diabetes [2].
- The Kidneys: Your kidneys are constantly pumping and filtering fluids, a process that requires intense energy. Mutations like m.3243A>G can damage the tubules (the filtering pipes) and podocytes (specialized cells), leading to chronic kidney disease [3].
- The Brain: The brain uses more energy than any other organ. Energy failure here can lead to seizures, strokes (often called stroke-like episodes), and loss of coordination or hearing [4][13].
The Path to Diagnosis: Testing Methods
Diagnosing these conditions can be a “detective story” because the mutation might be hiding in some tissues but not others. A general diagnostic pathway typically looks like this:
- Blood and Urine Tests: Doctors usually start with blood work, but for certain mutations (like m.3243A>G), testing urinary epithelial cells (cells shed in your urine) can sometimes provide a more accurate picture of the mutation load than blood [14][15].
- Next-Generation Sequencing (NGS): Modern labs use high-tech “dual-genome” panels that look at both the mtDNA and the nuclear DNA at the same time [14][7].
- The Role of Muscle Biopsy: If blood and urine tests are negative but your doctor still strongly suspects a mitochondrial issue, they may request a muscle biopsy. Muscle cells are very high-energy and often hold onto mutated mitochondria that have disappeared from the blood. This is an optional, specialist-directed test reserved for selected unresolved cases. A biopsy can also allow doctors to look at the cells under a microscope for ragged-red fibers, a finding that is supportive of mitochondrial struggle but is nonspecific and not strictly required to confirm disease [16][17][18].
Common questions in this guide
What causes proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome?
What does heteroplasmy mean in mitochondrial disease?
Can a blood test miss a mitochondrial DNA mutation?
Why can mitochondrial disease cause diabetes and kidney problems?
Is mitochondrial disease always inherited from the mother?
How is this mitochondrial syndrome diagnosed?
Should my family members have genetic counseling?
Get notified when new evidence is published on Proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
The molecular pathology of pathogenic mitochondrial tRNA variants.
Richter U, McFarland R, Taylor RW, Pickett SJ
FEBS letters 2021; (595(8)):1003-1024 doi:10.1002/1873-3468.14049.
PMID: 33513266 - 2
Toward Understanding the Molecular Basis and Precise Diagnosis of Mitochondrial Diabetes: A Comprehensive Review.
Skoczylas S, Banach K, Zmysłowska A
The Yale journal of biology and medicine 2026; (99(3)):466-487 doi:10.59249/GBKY6240.
PMID: 43005028 - 3
Chronic kidney disease caused by maternally inherited diabetes and deafness: a case report.
Tanaka K, Ueno T, Yoshida M, et al.
CEN case reports 2021; (10(2)):220-225 doi:10.1007/s13730-020-00547-w.
PMID: 33125665 - 4
Molecular biomarkers correlate with brain grey and white matter changes in patients with mitochondrial m.3243A > G mutation.
Evangelisti S, Gramegna LL, La Morgia C, et al.
Molecular genetics and metabolism 2022; (135(1)):72-81 doi:10.1016/j.ymgme.2021.11.012.
PMID: 34916127 - 5
Complex I deficiency in m.3243A>G fibroblasts is alleviated by reducing NADH accumulation.
Liufu T, Yu H, Yu J, et al.
Frontiers in physiology 2023; (14()):1164287 doi:10.3389/fphys.2023.1164287.
PMID: 37650111 - 6
Patient-Derived Fibroblasts as a Clinically Relevant Model of Kearns-Sayre Syndrome.
Valls-Roca L, Vilaseca-Capel A, Cantó-Santos J, et al.
Annals of neurology 2026; doi:10.1002/ana.78351.
PMID: 42753134 - 7
Experiences from dual genome next-generation sequencing panel testing for mitochondrial disorders: a comprehensive molecular diagnosis.
Gorman E, Dai H, Feng Y, et al.
Frontiers in genetics 2025; (16()):1488956 doi:10.3389/fgene.2025.1488956.
PMID: 40110048 - 8
Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches.
Nissanka N, Moraes CT
EMBO reports 2020; (21(3)):e49612 doi:10.15252/embr.201949612.
PMID: 32073748 - 9
Modulation of mtDNA copy number ameliorates the pathological consequences of a heteroplasmic mtDNA mutation in the mouse.
Filograna R, Koolmeister C, Upadhyay M, et al.
Science advances 2019; (5(4)):eaav9824 doi:10.1126/sciadv.aav9824.
PMID: 30949583 - 10
Heteroplasmy and Copy Number in the Common m.3243A>G Mutation-A Post-Mortem Genotype-Phenotype Analysis.
Scholle LM, Zierz S, Mawrin C, et al.
Genes 2020; (11(2)) doi:10.3390/genes11020212.
PMID: 32085658 - 11
Impact of measuring heteroplasmy of a pathogenic mitochondrial DNA variant at the single-cell level in individuals with mitochondrial disease.
Imai-Okazaki A, Nitta KR, Yatsuka Y, et al.
Journal of inherited metabolic disease 2022; (45(6)):1143-1150 doi:10.1002/jimd.12547.
PMID: 36053827 - 12
mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease.
Grady JP, Pickett SJ, Ng YS, et al.
EMBO molecular medicine 2018; (10(6)) doi:10.15252/emmm.201708262.
PMID: 29735722 - 13
Neurodegenerative and functional signatures of the cerebellar cortex in m.3243A > G patients.
Haast RAM, De Coo IFM, Ivanov D, et al.
Brain communications 2022; (4(1)):fcac024 doi:10.1093/braincomms/fcac024.
PMID: 35187487 - 14
Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines.
Mavraki E, Labrum R, Sergeant K, et al.
European journal of human genetics : EJHG 2023; (31(2)):148-163 doi:10.1038/s41431-022-01249-w.
PMID: 36513735 - 15
Analysis of Mutational Burden of Mitochondrial Genome in Cells of Different Human Organs and Tissues.
Sazonova MA, Sinyov VV, Ryzhkova AI, et al.
Current medicinal chemistry 2025; (32(15)):3028-3043 doi:10.2174/0109298673296881240816065357.
PMID: 39185646 - 16
Diagnosing Mitochondrial Disorders Remains Challenging in the Omics Era.
Forny P, Footitt E, Davison JE, et al.
Neurology. Genetics 2021; (7(3)):e597 doi:10.1212/NXG.0000000000000597.
PMID: 34056100 - 17
Investigation of oxidative phosphorylation activity and complex composition in mitochondrial disease.
Thompson K, Stroud DA, Thorburn DR, Taylor RW
Handbook of clinical neurology 2023; (194()):127-139 doi:10.1016/B978-0-12-821751-1.00008-7.
PMID: 36813309 - 18
Mitochondrial Myopathy in a 21-Year-Old Man Presenting With Bilateral Lower Extremity Weakness and Swelling.
Bharathidasan K, Evans A, Fernandez FMAO, et al.
Journal of primary care & community health 2023; (14()):21501319231172697 doi:10.1177/21501319231172697.
PMID: 37162197
This page explains the genetics and biology of proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome for informational purposes only and does not constitute medical advice. A mitochondrial disease specialist or genetic counselor should interpret your test results and advise you about your care.